Procalcitonin as a Biomarker of Unresponsiveness to Intravenous Immunoglobulin for Kawasaki Disease

Pediatr Infect Dis J. 2020 Sep;39(9):857-861. doi: 10.1097/INF.0000000000002716.

Abstract

Objective: To investigate the usefulness of procalcitonin (PCT) as predictive factors of intravenous immunoglobulin (IVIG)-resistant Kawasaki disease patients.

Methods: We retrospectively analyzed the laboratory data from 215 children with Kawasaki disease treated with IVIG from 2014 to 2019. We analyzed the clinical and laboratory parameters just before the IVIG including serum levels of PCT with respect to the IVIG response.

Results: Eventually, 127 patients were analyzed. The median age was 2.4 years. IVIG was effective in 108 children (responders) and was ineffective in 19 (non-responders). Serum PCT concentration was higher in non-responders than those of responders (P < 0.001). Multivariate logistic regression analyses indicated that higher PCT concentration (odds ratio 1.34, 95% confidence interval 1.10-1.64) were associated with IVIG resistance. Analyses of the receiver operating characteristic curve showed that the cutoff value of PCT 2.18 ng/mL had 46.4% of sensitivity and 93.9% of specificity. Receiver operating characteristic analysis yielded an area under the curve of 0.82 (0.72-0.92) to predict IVIG resistance.

Conclusions: Serum PCT value can be an excellent biomarker for predicting unresponsiveness to IVIG with a good discriminatory ability as well as the existing prediction scores.

MeSH terms

  • Biomarkers / blood
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Immunoglobulins, Intravenous / standards
  • Immunoglobulins, Intravenous / therapeutic use*
  • Infant
  • Logistic Models
  • Male
  • Mucocutaneous Lymph Node Syndrome / diagnosis
  • Mucocutaneous Lymph Node Syndrome / therapy*
  • Multivariate Analysis
  • Odds Ratio
  • Predictive Value of Tests
  • Procalcitonin / blood*
  • Procalcitonin / standards
  • Retrospective Studies
  • Treatment Failure

Substances

  • Biomarkers
  • Immunoglobulins, Intravenous
  • Procalcitonin